Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

Thorax

Volumn 68, Issue 6, 2013, Pages 532-539

  Horsley, Alex R ^a,b   Davies, Jane C ^a,c   Gray, Robert D ^a,d   MacLeod, Kenneth A ^a,e   Donovan, Jackie ^a,c   Aziz, Zelena A ^f   Bell, Nicholas J ^a,g   Rainer, Margaret ^a,g   Mt Isa, Shahrul ^h   Voase, Nia ^a,c   Dewar, Maria H ^a,i   Saunders, Clare ^a,c   Gibson, James S ^a,g   Parra Leiton, Javier ^a,g   Larsen, Mia D ^a,c   Jeswiet, Sarah ^a,c   Soussi, Samia ^a,c   Bakar, Yusura ^a,c   Meister, Mark G ^f   Tyler, Philippa ^f   Doherty, Ann ^a,g   Hansell, David M ^f   Ashby, Deborah ^h   Hyde, Stephen C ^a,j   Gill, Deborah R ^a,j   Greening, Andrew P ^a,i   Porteous, David J ^a,g   Alastair Innes, J ^a,i   Christopher Boyd, A ^a,g   Griesenbach, Uta ^a,c   Cunningham, Steve ^a,e   Alton, Eric W F W ^a,c   more..

^a UK Cystic Fibrosis Gene Therapy Consortium   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ WESTERN GENERAL HOSPITAL   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; GAMMA INTERFERON; INTERLEUKIN 6;

ADULT; AGED; AIR ANALYSIS; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE INDEX; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG STRUCTURE; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM;

EID: 84877593162     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202538     Document Type: Article

References (34)

1. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-5. (Pubitemid 27066337)
2. Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007;4:299-301. (Pubitemid 47330859)
3. EMA. Guideline on the Clinical Development of Medicinal Products for the Treatment of Cystic Fibrosis. London: European Medicines Agency, 2009.
4. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175:943-50. (Pubitemid 46684705)
5. Robinson PD, Cooper P, Van Asperen P, et al. Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2009;44:733-42.
6. Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 2005;40:15-21. (Pubitemid 40917903)
7. Cunningham S, McColm JR, Mallinson A, et al. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr Pulmonol 2003;36:43-8. (Pubitemid 36734765)
8. Norman D, Elborn JS, Cordon SM, et al. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 1991;46:91-5.
9. Downey DG, Brockbank S, Martin SL, et al. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007;42:729-35. (Pubitemid 47242871)
10. Shah RM, Sexauer W, Ostrum BJ, et al. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR 1997;169:375-80. (Pubitemid 27334844)
11. Brody AS, Molina PL, Klein JS, et al. High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999;29:731-5. (Pubitemid 29450139)
12. Newport S, Amin N, Dozor AJ. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations. Pediatr Pulmonol 2009;44:866-72.
13. Roderfeld M, Rath T, Schulz R, et al. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros 2009;8:338-47.
14. Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010;9:193-8.
15. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177:253-60. (Pubitemid 351198367)
16. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
17. Rosenthal M, Bain SH, Cramer D, et al. Lung function in white children aged 4 to 19 years: I-Spirometry. Thorax 1993;48:794-802. (Pubitemid 23244340)
18. Horsley AR, Gustafsson PM, Macleod KA, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax 2008;63:135-40. (Pubitemid 351236478)
19. Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008;178:444-52.
20. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000;55:198-204. (Pubitemid 30245969)
21. Bell SC, Bowerman AM, Nixon LE, et al. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000;30:553-9. (Pubitemid 30330471)
22. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007;4:378-86. (Pubitemid 47330875)
23. Modi AC, Lim CS, Driscoll KA, et al. Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations. J Clin Psychol Med Settings 2010;17:49-55.
24. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-18.
25. Tiddens HA, Donaldson SH, Rosenfeld M, et al. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 2010;45:107-17.
26. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003;22:972-9. (Pubitemid 37540651)
27. Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011;37:806-12.
28. Mentore K, Froh DK, De Lange EE, et al. Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol 2005;12:1423-9. (Pubitemid 41512835)
29. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-17. (Pubitemid 47330878)
30. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-8. (Pubitemid 46631794)
31. Golden BE, Clohessy PA, Russell G, et al. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Childhood 1996;74:136-9. (Pubitemid 26057695)
32. Brody AS, Klein JS, Molina PL, et al. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-8. (Pubitemid 38962449)
33. Aziz ZA, Wells AU, Meister M, et al. Computed tomography in infective exacerbations of cystic fibrosis: serial change and observer agreement. Thorax 2007;62(Suppl III):A30.
34. Alton EW, Boyd AC, Cunningham S, et al. Longitudinal assessment of biomarkers for clinical trials of novel therapeutic agents: the run-in study. Pediatr Pulmonol 2010;11(Suppl 33):298.